Lessons Learned from Assembling Screening Libraries for Drug Discovery
Author Information
Author(s): Ruth Brenk, Alessandro Schipani, Daniel James, Agata Krasowski, Ian Gilbert, Hugh Frearson, Julie Wyatt, Paul Graham
Primary Institution: University of Dundee, College of Life Sciences, James Black Centre
Hypothesis
To establish a drug discovery operation for neglected diseases, a robust strategy for compound selection is necessary.
Conclusion
The study successfully compiled diverse screening libraries that span a broad range of lead-like chemical space and show good quality for drug discovery.
Supporting Evidence
- The study selected 222,552 compounds for a virtual screening library.
- The selected compounds cover a broad range of lead-like chemical space.
- The majority of compounds showed high purity and structural integrity.
- Only 1.3% of the compounds were found to have solubility issues.
Takeaway
The researchers created a collection of compounds to help find new medicines for diseases that are often ignored, making sure the compounds are good starting points for further research.
Methodology
The study involved assembling three different libraries: a virtual screening library, a diverse screening library, and a focused kinase library, followed by rigorous filtering and selection criteria.
Potential Biases
The selection process may be influenced by the experience and intuition of the medicinal chemists involved.
Limitations
The study acknowledges gaps in the commercial compound space, particularly for certain core fragments.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website